IndustryCompany release

Scienture Q3 revenue reaches $1.25M as REZENOPY naloxone nasal spray launches

🇺🇸 Scienture Holdings, Inc. (SCNX) · Thu 19 Nov 2026

The US company reports roughly 265% sequential revenue growth, led by initial wholesale sales of its naloxone nasal spray, while still posting a net loss of about $6.0m.

Scienture Holdings reported third-quarter 2026 revenue of $1.25m, around 265% higher than in the second quarter. The increase was driven mainly by initial wholesale sales of REZENOPY (naloxone hydrochloride nasal spray 10 mg), which the company launched in August 2026 and which contributed roughly $925,000.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Scienture Holdings, Inc. ↗

Article written by VigiEye from the official source (Scienture Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →